Lovenox treatment lowered the risk of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE).1
Outcomes of medical patients with restricted mobility treated with 7 days (median duration) of 40 mg Lovenox daily subcutaneously:
Relative risk reduction of
63%
and ARR=7.5% in DVT/PE events;
Lovenox
vs placebo (4.4% vs 11.9%);
P=0.0003a;
N=722.
At approximately 3 months following enrollment, the incidence of venous thromboembolism remained lower in the Lovenox 40 mg treatment group versus the placebo treatment group.
Safety endpoints (Lovenox vs placebo)1
Major bleeding: 3(<1%) vs 2(<1%)
Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of >= 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial. The rates represent major bleeding on study medication up to 24 hours after last dose.
In a study of medical patients with severely restricted mobility during acute illness, Lovenox was dosed for no more than 14 days, and most patients were treated for 6 to 11 days in this study (median 7 days).
ARR=absolute risk reduction
aP value calculated based on chi-square test.1
